Current models and strategies in the development of antiobesity drugs

Kinsey‐Jones, James S.; Murphy, Kevin G.
December 2011
Annals of the New York Academy of Sciences;Dec2011, Vol. 1245 Issue 1, p3
Academic Journal
Animal models have enabled investigation of the complex mechanisms underlying energy homeostasis and, therefore, the development of antiobesity drugs.


Related Articles

  • The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes. Hollander, Priscilla // U.S. Endocrinology;Winter2013, Vol. 9 Issue 2, p101 

    The prevalence of diabetes continues to rise, following the rising rates of obesity. Obesity is not only associated with an increased risk for developing type 2 diabetes but also an elevated probability of developing long-term complications associated with the disease. Weight gain is also an...

  • Diet 'wonder drug' approved. O'Driscoll, Cath // ICIS Chemical Business;7/10/2006, Vol. 1 Issue 27, p31 

    The article reports that the weight-loss drug Acomplia (rimonabant) from Sanofi-Aventis has been approved for use in all 25 European Union member states. The first in a class of drugs called CB1 blockers, the pill has been licensed for use as an adjunct to diet for obese or overweight patients...

  • Screening of Crude Plant Extracts with Anti-Obesity Activity. Changhyun Roh; Uhee Jung // International Journal of Molecular Sciences;Feb2012, Vol. 13 Issue 2, p1710 

    Obesity is a global health problem. It is also known to be a risk factor for the development of metabolic disorders, type 2 diabetes, systemic hypertension, cardiovascular disease, dyslipidemia, and atherosclerosis. In this study, we screened crude extracts from 400 plants to test their...

  • Economic Impact of Moderate Weight Loss in Type 2 Diabetes: The Fremantle Diabetes Study. Davis, Wendy A.; Davis, Timothy M. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA267 

    Overweight and obesity complicate the management of type 2 diabetes. Moderate weight loss (5% body weight) improves glycemic control and reduces cardiovascular disease risk but its sustainability can be problematic. We assessed the economic impact of moderate weight loss among 730 type 2...

  • Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes. Skelley, Jessica W; Carter, Brooke S; Roberts, Megan Z // Vascular Health & Risk Management;Dec2018, Vol. 14, p419 

    Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes mellitus, as well as the leading diabetes-associated health care cost. The prevalence and associated impact of cardiovascular disease among those with diabetes engenders the need to identify...

  • Eneteromedics reports Aussie study results.  // Medical Device Daily;11/16/2010, Vol. 14 Issue 223, p6 

    The article reports on the results presented by Enteromedics from its EMPOWER clinical trial and a caloric intake study of VBLOC vagal blocking therapy delivered via the Maestro system. The former is a multi-center, randomized, double-blind, prospective, placebo-controlled pivotal study which...

  • Does the length of the biliary limb influence medium-term laboratory remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass in morbidly obese patients? Kaska, Łukasz; Kobiela, Jarek; Proczko, Monika; Stefaniak, Tomasz; Śledziński, Zbigniew // Videosurgery & Other Miniinvasive Techniques / Wideochirurgia i;Mar2014, Vol. 2014 Issue 1, p31 

    Introduction: The Roux-en-Y gastric bypass (RYGB) is an effective treatment of morbid obesity leading to type 2 diabetes mellitus (T2DM) resolution. However, evidence demonstrates that standard limb lengths can have a limited impact on long-term weight loss and durable T2DM remission. Aim: The...

  • The efficacy of bariatric surgery performed in the public sector for obese patients with comorbid conditions. Lukas, Natalie; Franklin, Janet; Lee, Crystral M. Y.; Taylor, Craig J.; Martin, David J.; Kormas, Nic; Caterson, Ian D.; Markovic, Tania P. // Medical Journal of Australia;8/18/2014, Vol. 201 Issue 4, p218 

    The article presents a study that determines the efficacy of bariatric surgery for complicated obesity treatment. The study participants who underwent bariatric surgery were obese people aged 21-73 years with comorbid conditions. Moreover, the main outcome measures include postoperative weight...

  • Dynamic Lung Function Tests in Obese. Kotur, Naveen S.; Hiremath, S. C.; Sappandi, Nanda B.; Gurupadappa, K. // Journal of Pharmaceutical Sciences & Research;2012, Vol. 4 Issue 1, p1681 

    Obesity is a far-reaching problem worldwide today. It is more prevalent than ever and millions of people are at risk for number of diseases like type II diabetes, dyslipidaemia, derangement of pulmonary functions and cardiovascular diseases. The negative association between obesity and pulmonary...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics